Shionogi & Co.
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 8 disclosed transactions, Shionogi & Co. concentrates its licensing activity in InfectiousDisease, Metabolic, and Neurology. Shionogi & Co. pays a 0.92x discount to market median. Their most common deal structure is License, with an average disclosed value of $458M. Most recent activity: 2026.
Pipeline coverage & gaps
Shionogi & Co. has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 3 | $107M | $625M |
| Acquisition | 2 | $100M | $145M |
| Collaboration | 2 | $100M | $480M |
| Option | 1 | $6M | $542M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Shionogi-Apnimed Sleep Science (SASS) joint venture stake | Apnimed | obstructive sleep apnea | phase_2 | $100M | $150M |
| 2025 | BV500 | BioVersys AG | mycobacterial disease | discovery | $6M | $542M |
| 2024 | MZE001 and related GYS1-modulating compounds | Maze Therapeutics | phenylketonuria (PKU) and Pompe disease | preclinical | $150M | $755M |
| 2024 | MZE001 and GYS1-modulating compounds | Maze Therapeutics | metabolic disease (GYS1-related) | phase_1 | $150M | $755M |
| 2023 | xeruborbactam | Qpex Biopharma | bacterial infections (AMR) | preclinical | $100M | $140M |
| 2022 | QPX7728 | Qpex Biopharma | Drug-Resistant Gram-Negative Infections | phase_1 | $20M | $365M |
| 2022 | Olorofim | F2G Ltd. | invasive aspergillosis | phase_2 | $100M | $480M |
| 2022 | olorofim | F2G Ltd. | fungal infections | phase_2 | $100M | $480M |
How this is computed
For each Shionogi & Co. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 0.915, clamped to [0.7, 1.5].